Table 1.
Baseline characteristics
| Low dose | Normal dose [14] | |
|---|---|---|
| Demographic patient data | ||
| Number of patients | 84 | 14 |
| Male, n (%) | 39 (46) | 7 (50) |
| Age (years) | 4.29 (0.0–18.8) | 3.79 (0–16.6) |
| Height (cm) | 103.0 (50–176) | 101.5 (50–184) |
| Weight (kg) | 16.15 (2.4–89) | 14.5 (3.4–57.5) |
| BSA (m2) | 0.69 (0.19–2.10) | 0.65 (0.23–1.68) |
| Patient diagnosis | ||
| PA + VSD/TOF, n (%) | 23 (27.4) | 4 (28.6) |
| Aortic pathology, n (%) | 20 (23.8) | 3 (21.4) |
| Univentricular heart, n (%) | 19 (22.6) | 2 (14.3) |
| TGA, n (%) | 6 (7.1) | 2 (14.3) |
| Genetic syndrome, n (%) | 8 (9.5) | 0 (0) |
| Others, n (%) | 8 (9.5) | 3 (21.4) |
| Procedural data | ||
| Number of 3DRAs | 100 | 17 |
| Interventional procedures, n (%) | 75 (75) | 12 (71) |
Continuous variables are summarized as median and range, and categorical variables are reported as number of cases (n) and percentage
BSA body surface area, PA pulmonary atresia, TGA transposition of the great arteries, TOF tetralogy of fallot, VSD ventricular septal defect